Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20993450 | 1.00 | GLP1R (0.54) | GLP1RNOD1FOLH1EPHX2GLO1 | |
| SCHEMBL22024420 | 0.91 | GLP1R (0.55) | GLP1RNOD1FOLH1EPHX2GLO1 | |
| SCHEMBL24352155 | 0.89 | GLP1R (0.53) | GLP1RNOD1FOLH1EPHX2GLO1 | |
| SCHEMBL22585863 | 0.89 | GLP1R (0.63) | GLP1RNOD1FOLH1EPHX2GLO1 | |
| SCHEMBL22585862 | 0.88 | GLP1R (0.62) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL22586437 | 0.88 | GLP1R (0.62) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL25726353 | 0.88 | GLP1R (0.59) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL21789855 | 0.87 | GLP1R (0.52) | GLP1RNOD1FOLH1EPHX2GLO1 | |
| SCHEMBL22585861 | 0.87 | GLP1R (0.64) | GLP1RNOD1FOLH1GLO1 | |
| SCHEMBL20750829 | 0.87 | GLP1R (0.64) | GLP1RNOD1FOLH1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | GLP1R 3544/4885NOD1 808/4885FOLH1 2436/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | GLP1R 3544/4885NOD1 808/4885FOLH1 2436/4885 |
| US-20210300934-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | GLP1R 4432/4885NOD1 1289/4885FOLH1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.